Nhà máy Stada
Stada
stada
stada
Antibiotics

scanax 500

 

Pack size:

Alu/Alu or PVC/Alu blister.

Box of 5 blisters x 10 tablets.


Composition:

Each film-coated-tablet contains ciprofloxacin (hydrochloride) 500 mg.

 

Shelf-life:

48 months from the date of manufacturing.

Store in a well-closed container, in a dry place.

Protect from light. Do not store above 30oC.
 
 

  • Indications and Dosage & Administration
  • Contraindications
  • Adverse reactions
  • Precautions

  • Severe infection, when other usual antibiotics are not effective, in order to limit the development of ciprofloxacin resistant bacteria: Upper urinary tract infections, prostatitis, bone-marrow infections, severe bacterial enteritis, severe nosocomial infections (septicemia, immuno-deficiency diseases).
  • Prophylaxis of meningococcal meningitis and infection diseases in immunocompromised patients.
     
  • The drug should be given 2 hours after a meal. The patient should drink fluids liberally and not take antacids within 2 hours after digestion.
  • For the majority of cases the treatment should be continued for at least 48 hours, after all disease symptoms have been disappeared. Treatment time is usually 1-2 weeks, but for severe infection with complication, this time should be prolonged.
  • In cases of bone or joint infection, the ciprofloxacin treatment must be continued for 4 - 6 weeks or more long. Infectious diarrhea can be treated within 3-7 days or in a shorter time.
     
  • Dosage per 24 hours
    Upper urinary tract infection: 500 mg x 2.
    Uncomplicated gonorrhea: 500 mg, single dose.
    Chronic prostatitis: 500 mg x 2.
    Infections in skin, soft tissues and bone: 500 mg x 2.
    Severe bacterial enteritis: Treatment: 500 mg x 2/day; prophylaxis: 500 mg x 1.
    Prophylaxis against meningococcal diseases: Adults and children > 20 kg: 500 mg, single dose.
    Prophylaxis against Gram (-) infections in immune suppressed patients: 500 mg x 2.
    Severe nosocomial infections (septicemia and treatment of infections in immune suppressed patients): 500 mg x 2


    Patients with impaired liver function: No dose adjustment is required.
     

Or as prescribed by physicians.
 

  • Hypersensitivity to ciprofloxacin or other quinolones or to any ingredient of the drug.
  • Concomitant administration of ciprofloxacin and tizanidine.

     

Common

  • Nausea, vomiting, diarrhoea, abdominal pain.
  • Transient increases in serum transaminases.

Less common

  • Headache, drug induced fever.
  • Eosinophilia, leukocytopenia, granulocytopenia, anaemia, thrombocytopenia.
  • Tachycardia.
  • Agitation.
  • Dyspepsia.
  • Exanthema, pruritus.
  • Transient elevation of creatinine, bilirubin and alkaline phosphatases.
  • Joints pain and swelling.

Rare

  • Anaphylactic or anaphylactoid reactions.
  • Haemolytic anaemia, lekocytosis, thrombocytosis, altered prothrombin levels.
  • Seizures, confusion, psychotic reactions, hallucinations, sleep disturbances, depression, peripheral paresthesis, visual disturbances including hallucinations, hearing impairment, tinnitus, altered taste and smell, elevated intracranial pressure.
  • Pseudo-membraneous colitis.
  • Mucocutaneous syndrome, Lyell's syndrome, erythema nodosum, erythema exsudativum multiforme.
  • Cases of hepatocellular necrosis reported, hepatitis, jaundice due to cholestasis.
  • Muscle pain, inflammation in tendon and surrounding tissue.
  • Crystalluria at alkaline urine, haematuria, acute renal failure, interstitial nephritis.

Other

  • Photosensitivity when sun-exposed, laryngeal or pulmonary oedema, dyspnea, bronchospasm.

     

  • Caution in patients with epilepsy or a history of CNS disorders, renal impairment, G6DP deficiency, or myasthenia gravis.
  • Treatment should be stopped if patients experience tendon pain, inflammation, or rupture.
  • Exposure to strong sunlight or sunlamp should be avoided during treatment with ciprofloxacin.
  • Ciprofloxacin and other fluoroquinolones should be avoided in Methicillin-resistant Staphylococcus aureus (MRSA) infections because of the high level of resistance.
  • Ciprofloxacin may cause negative of the bacteriological tests of Mycobacterium tuberculosis.
  • Experimentally, ciprofloxacin may cause degeneration in weight-bearing joints in young animals. This should be taken into account when prescribing ciprofloxacin to children and growing adolescents.
  • Pregnancy: Ciprofloxacin is only used for pregnancy with severe infection that was not manageable with therapeutic dosages of other antibiotic agents, use of fluoroquinolon is an obligatory therapy.
  • Lactation: Ciprofloxacin is excreted in human milk. Because of the potential for serious adverse reactions in infants nursing from mother taking ciprofloxacin. If continued use is considered obligatory, mother should discontinue nursing.
  • The ability to drive or operate machinery may be impaired, especially when alcohol is also taken.

     

Contact us

FACTORY 1: K63/1 Nguyen Thi Soc St., Xuan Thoi Dong, Hoc Mon, HCMC
Tel: +84 28 3718 2141 - Fax: +84 28 3718 2140

FACTORY 2: 40 Tu Do Avenue, VietNam-Singapore Industrial Park, Binh Duong
Tel: +84 274 376 7470 - Fax: +84 274 376 7469
Email : stada@stada.com.vn
Website: www.stada.com.vn



Visitors Counter

Online
19
Total